Home / Pharmaceutical company intelligence
M/s Daneen Pharma (Pvt) Ltd logo
Pharmaceutical company intelligence

M/s Daneen Pharma (Pvt) Ltd

Private pharmaceutical manufacturer · Lahore · Pakistan

Lahore-based branded-generics pharmaceutical manufacturer with a modern manufacturing facility at Sundar Industrial Estate.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check9 Aug 2026Latest source-check date across this published portfolio
Latest effective price date22 Jul 2026Newest effective date among published current price records
Corporate profile evidence5 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Legal / official name
Daneen Pharma (Private) Limited
Company type
Private pharmaceutical manufacturer
Address
27, Sundar Industrial Estate, Sundar, Raiwind Road, Lahore 53801, Pakistan · 53801
Phone
+92 21 111 10 10 11
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
88%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000688 Daneen Pharma (Pvt) Ltd. · Punjab
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000688 93 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Logo Url source ↗ Contact Page Url source ↗ Logo Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx95public portfolio records represented
REG79unique registrations represented
IDX93indexed MedInfoBase presentations
SRC1additional source-observed presentations
R+1registry-only registrations
VER0registry-verified exact registrations
PKR93current validated price records
G33generic molecules in indexed catalogue
DF5dosage-form groups
TA7therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage98%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage94%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixM/s Daneen Pharma (Pvt) LtdShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/m-s-daneen-pharma-pvt-ltdGenerated 23 Sep 2026Anti-infectives52 · 56%CNS & mental health18 · 19%Cardiovascular13 · 14%Gastrointestinal & hepatology5 · 5%Oncology & immunology2 · 2%Endocrine & metabolic2 · 2%Pain & musculoskeletal1 · 1%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioM/s Daneen Pharma (Pvt) LtdDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/m-s-daneen-pharma-pvt-ltdGenerated 23 Sep 202693presentationsTablet61 · 66%Injection22 · 24%Suspension5 · 5%Capsule4 · 4%Infusion1 · 1%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionM/s Daneen Pharma (Pvt) LtdCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/m-s-daneen-pharma-pvt-ltdGenerated 23 Sep 202687comparable productsBelow peer median25 · 29%Near peer median41 · 47%Above peer median21 · 24%Company median price position+0.0%Lowest-price equivalents8Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsM/s Daneen Pharma (Pvt) LtdCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/m-s-daneen-pharma-pvt-ltdGenerated 23 Sep 2026M/s. Genix Pharma (Pvt) Ltd.31 shared94% overlapNabiqasim Industries (Pvt) Ltd.,26 shared79% overlapNeutro Pharma (Pvt.) Ltd.,25 shared76% overlapBio-Labs(Pvt) Ltd24 shared73% overlapHIGH-Q Pharmaceuticals24 shared73% overlapPharmasol (Pvt) Ltd.23 shared70% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives52 products · 56%
CNS & mental health18 products · 19%
Cardiovascular13 products · 14%
Gastrointestinal & hepatology5 products · 5%
Oncology & immunology2 products · 2%
Endocrine & metabolic2 products · 2%
Pain & musculoskeletal1 products · 1%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins14 products · 15%
Antiepileptics13 products · 14%
Calcium-channel blockers11 products · 12%
Antivirals8 products · 9%
Macrolide antibacterials7 products · 8%
Antimalarials6 products · 6%
Antipsychotics5 products · 5%
Fluoroquinolone antibacterials5 products · 5%
Formulation footprint

Dosage forms

Tablet61 products
Injection22 products
Suspension5 products
Capsule4 products
Infusion1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 Nadsar-ATelmisartan + Amlodipine 11presentations 10 mg + 10 mg, 40 mg + 10 mg, 5 mg + 5 mg, 80 mg + 10 mg · Tablet #2 SaltamLevetiracetam 9presentations 1000 mg, 250 mg, 500 mg, 750 mg · Tablet #3 BlucefCeftriaxone 6presentations 1 g, 2 g, 250 mg, 500 mg · Injection #4 XintherClarithromycin 5presentations 250 mg, 250 mg/5 mL, 500 mg · Tablet, Suspension, Injection #5 ErbivirEntecavir 4presentations 0.5 mg, 1 mg · Tablet #6 LamtrigLamotrigine = 4presentations 100 mg, 150 mg, 200 mg, 25 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median2529% of comparable products
Near market median41within ±5% of median
Above market median2124% of comparable products
Lowest-price equivalents8ties included
Company median price position +0.0% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Olmepra 40 mgOmeprazole · Capsule · 14's PKR 20.68/capsule-40.3% vs market median Fordim 250 mgLevofloxacin · Tablet · 10's PKR 29.12/tablet-39.6% vs market median Olmepra 20 mgOmeprazole · Capsule · 14's PKR 11.91/capsule-39.5% vs market median Roxdan 750 mgCefuroxime · Injection · 1's PKR 115.83/vial/unit-39.4% vs market median Glimfempa 25 mgEmpagliflozin · Tablet · 14's PKR 64.36/tablet-36.0% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

M/s. Genix Pharma (Pvt) Ltd.297 products · 97 generics 31shared generics Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 26shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 25shared generics Bio-Labs(Pvt) Ltd236 products · 82 generics 24shared generics HIGH-Q Pharmaceuticals215 products · 61 generics 24shared generics Pharmasol (Pvt) Ltd.257 products · 102 generics 23shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers77Distinct registrations among indexed, published, presentation-validated products only
Verified price observations93
Products with a verified price93
Products with multiple price observations0
Source records with multiple versions93
Latest portfolio source check9 Aug 2026
Latest effective price date22 Jul 2026
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

79 unique registration(s) · 93 indexed presentation(s) · 1 additional source-observed presentation(s) · 1 registry-only registration(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Ardan Artesunate 30 mg Powder for injection 1's 100732 PKR 132.96 PKR 132.96/vial/unit No comparator
Ardan Artesunate 60 mg Powder for injection 1's 100733 PKR 221.59 PKR 221.59/vial/unit No comparator
Ardan Artesunate 120 mg Powder for injection 1's 100734 PKR 369.31 PKR 369.31/vial/unit No comparator
Blucef Ceftriaxone 250 mg IV injection 1's 064692 PKR 196.09 PKR 196.09/vial/unit Near median
Blucef Ceftriaxone 1 g IV injection 1's 064693 PKR 623.22 PKR 623.22/vial/unit Near median
Blucef Ceftriaxone 500 mg IV injection 1's 064695 PKR 330.04 PKR 330.04/vial/unit Near median
Blucef Ceftriaxone 250 mg IM injection 1's 067709 PKR 196.09 PKR 196.09/vial/unit Near median
Blucef Ceftriaxone 500 mg IM injection 1's 067710 PKR 330.04 PKR 330.04/vial/unit Near median
Blucef Ceftriaxone 2 g Injection 1's 119584 PKR 929.36 PKR 929.36/vial/unit 15% above median
Canon Vancomycin 500 mg Powder for injection 1's 099131 PKR 1,292.61 PKR 1,292.61/vial/unit No comparator
Confentrin Artemether + Lumefantrine 120 mg + 120 mg Tablet 16's 108371 PKR 660.89 PKR 41.31/tablet 7% below median
ConfentrinSource observed Artemether + Lumefantrine 80 mg Tablet 8's 108372Official source ↗ No indexed price — —
Confentrin Artemether + Lumefantrine 40 mg + 240 mg Tablet 8's 110803 PKR 601.53 PKR 75.19/tablet 17% above median
Danclave Aciclovir 200 mg Tablet 10's 106998 PKR 426.55 PKR 42.66/tablet 18% above median
Danclave Aciclovir 800 mg Tablet 20's 106999 PKR 1,535.57 PKR 76.78/tablet 7% above median
Danclave Aciclovir 400 mg Tablet 35's 107000 PKR 2,388.66 PKR 68.25/tablet 15% above median
Danletro Letrozole 2.5 mg Tablet 10's 110601 PKR 4,931.75 PKR 493.18/tablet 23% above median
Danletro Letrozole 2.5 mg Tablet 30's 110601 PKR 14,795.25 PKR 493.18/tablet 23% above median
Dprofen Ibuprofen 600 mg/100 mL IV infusion 100ml Vial 123712 PKR 271.62 PKR 2.72/mL Near median
Drisper Disintegranting Risperidone 4 mg Tablet 10's 124314 PKR 805.45 PKR 80.55/tablet 11% above median
Erbivir Entecavir 0.5 mg Tablet 30's 102413 PKR 9,098.12 PKR 303.27/tablet 15% below median
Erbivir Entecavir 0.5 mg Tablet 10's 102413 PKR 3,296.15 PKR 329.62/tablet 7% below median
Erbivir Entecavir 1 mg Tablet 30's 102414 PKR 15,162.32 PKR 505.41/tablet 15% below median
Erbivir Entecavir 1 mg Tablet 10's 102414 PKR 5,493.59 PKR 549.36/tablet 7% below median
Fordim Levofloxacin 250 mg Tablet 10's 078784 PKR 291.22 PKR 29.12/tablet 40% below median
Fordim Levofloxacin 500 mg Tablet 10's 078785 PKR 621.27 PKR 62.13/tablet 21% below median
Glimfempa Empagliflozin 10 mg Tablet 14's 121428 PKR 752.78 PKR 53.77/tablet 35% below median
Glimfempa Empagliflozin 25 mg Tablet 14's 121429 PKR 901.01 PKR 64.36/tablet 36% below median
Harod Ciprofloxacin 250 mg Tablet 10's 078786 PKR 252.39 PKR 25.24/tablet Near median
Harod Ciprofloxacin 500 mg Tablet 10's 078787 PKR 417.41 PKR 41.74/tablet Near median
Hedqin 40 Dihydroartemisinin + Piperaquine 40 mg + 320 mg Tablet 8's 109415 PKR 676.29 PKR 84.54/tablet Near median
Imlax Cephalexin 250 mg Capsule 12's 101554 PKR 188.36 PKR 15.70/capsule Near median
Imlax Cephalexin 125 mg/5 mL Suspension 60ml 101555 PKR 108.94 PKR 1.82/mL Near median
Imlax Cephalexin 250 mg/5 mL Suspension 60ml 101556 PKR 188.36 PKR 3.14/mL Near median
Kezidime Ceftazidime 500 mg Injection 1's 064694 PKR 255.31 PKR 255.31/vial/unit Near median
Kezidime Ceftazidime 250 mg Injection 1's 064700 PKR 167.85 PKR 167.85/vial/unit Near median
Lamtrig Lamotrigine = 100 mg Tablet 30's 109416 PKR 1,081.10 PKR 36.04/tablet Near median
Lamtrig Lamotrigine = 150 mg Tablet 30's 109417 PKR 1,297.32 PKR 43.24/tablet 5% above median
Lamtrig Lamotrigine = 200 mg Tablet 30's 109418 PKR 1,513.54 PKR 50.45/tablet Near median
Lamtrig Lamotrigine = 25 mg Tablet 30's 109419 PKR 648.66 PKR 21.62/tablet Near median
LZL Linezolid 400 mg Tablet 12's 109420 PKR 3,056.95 PKR 254.75/tablet 11% above median
LZL Linezolid 600 mg Tablet 12's 109421 PKR 5,351.75 PKR 445.98/tablet 13% above median
Moxdan Moxifloxacin 400 mg Tablet 5's 078781 PKR 922.20 PKR 184.44/tablet Near median
Nadsar-A Telmisartan + Amlodipine 80 mg + 10 mg Tablet 10's 106991 PKR 886.50 PKR 88.65/tablet Near median
Nadsar-A Telmisartan + Amlodipine 10 mg + 10 mg Tablet 14's 106991 PKR 1,243.27 PKR 88.81/tablet 51% above median
Nadsar-A Telmisartan + Amlodipine 40 mg + 10 mg Tablet 30's 106992 PKR 1,617.33 PKR 53.91/tablet Near median
Nadsar-A Telmisartan + Amlodipine 10 mg + 10 mg Tablet 14's 106992 PKR 821.64 PKR 58.69/tablet 34% below median
Nadsar-A Telmisartan + Amlodipine 40 mg + 10 mg Tablet 10's 106992 PKR 585.96 PKR 58.60/tablet 8% above median
Nadsar-A Telmisartan + Amlodipine 40 mg + 10 mg Tablet 20's 106992 PKR 1,113.54 PKR 55.68/tablet Near median
Nadsar-A Telmisartan + Amlodipine 80 mg + 5 mg Tablet 30's 106993 PKR 2,138.41 PKR 71.28/tablet Near median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). M/s Daneen Pharma (Pvt) Ltd — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/m-s-daneen-pharma-pvt-ltd/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.